$6.87 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter

Equities research analysts forecast that Radius Health Inc (NASDAQ:RDUS) will report sales of $6.87 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Radius Health’s earnings, with estimates ranging from $6.39 million to $7.35 million. The company is scheduled to announce its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Radius Health will report full year sales of $6.87 million for the current fiscal year, with estimates ranging from $20.84 million to $21.79 million. For the next fiscal year, analysts forecast that the firm will report sales of $77.47 million per share, with estimates ranging from $60.85 million to $94.08 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Radius Health.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter last year, the firm earned ($1.07) EPS.

RDUS has been the topic of several analyst reports. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the company a “buy” rating in a report on Friday, December 15th. Jefferies Group decreased their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. Citigroup assumed coverage on shares of Radius Health in a report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 price objective on the stock. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Finally, Maxim Group restated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Radius Health currently has a consensus rating of “Hold” and an average price target of $48.00.

In related news, VP Brent Hatzis-Schoch acquired 1,778 shares of Radius Health stock in a transaction on Friday, November 10th. The shares were purchased at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the purchase, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction on Tuesday, November 14th. The shares were bought at an average price of $26.25 per share, for a total transaction of $1,312,500.00. Following the completion of the purchase, the insider now directly owns 5,698,799 shares in the company, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders bought 158,578 shares of company stock valued at $4,659,916 over the last 90 days. Insiders own 15.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. BB Biotech AG raised its holdings in shares of Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after purchasing an additional 498,400 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after purchasing an additional 569,300 shares during the period. Vanguard Group Inc. raised its holdings in shares of Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after purchasing an additional 135,071 shares during the period. BlackRock Inc. raised its holdings in shares of Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after purchasing an additional 262,896 shares during the period. Finally, State Street Corp increased its holdings in shares of Radius Health by 12.9% in the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after acquiring an additional 213,399 shares during the period.

Shares of Radius Health (NASDAQ:RDUS) traded up $0.01 during trading hours on Friday, hitting $33.30. 570,900 shares of the stock traded hands, compared to its average volume of 605,633. The stock has a market capitalization of $1,490.00, a P/E ratio of -6.13 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16.

COPYRIGHT VIOLATION WARNING: “$6.87 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/05/6-87-million-in-sales-expected-for-radius-health-inc-rdus-this-quarter.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply